Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

30-05-2020 | ASCO 2020 | Conference coverage | Video

Researcher comment: Dual EGFR inhibition for EGFR-mutated NSCLC

Julia Rotow outlines the rationale and preliminary findings of a study of concurrent osimertinib and gefitinib for treatment-naïve EGFR-mutated non-small-cell lung cancer (6:59).

External Content

Click Play to display this content and agree to third party cookies. (>)

Update your current cookie settings.

Read transcript

Related content

16-08-2018 | Non-small-cell lung cancer | Article

Management of EGFR mutation-positive non-small-cell lung cancer: Two steps forward, looking back

28-10-2019 | Non-small-cell lung cancer | Highlight | News

Network meta-analysis identifies best clinical choices for EGFR-mutated NSCLC

29-09-2019 | Non-small-cell lung cancer | Video | Article

Researcher comment: Positive OS data for osimertinib in FLAURA trial

20-11-2019 | Non-small-cell lung cancer | News

More support for gefitinib–chemotherapy combination in EGFR-mutated NSCLC
Image Credits